CARB-X Funds Vedanta Biosciences
Vedanta’s VE707 microbiome program is designed to accelerate the development of a new category of oral therapeutics to help a patient’s microbiota fight drug-resistant bacteria.
CARB-X Funds VenatoRx to Support Development of New Class of Oral Antibiotics to Treat Multi-Drug-Resistant Gonorrhoea
Kevin Outterson and CARB-X featured in Pharmaceutical Business Review.
T2 Biosystems Announces Granting of CE-Mark for T2Resistance Panel
The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections
CARB-X Funds Techulon to Support the Development of Innovative Nano Therapeutics Capable of Killing Drug-Resistant Bacteria by Precisely Targeting Essential Genes
Techulon project is the 50th project funded by CARB-X since it was launched in 2016. (BOSTON, MA) – CARB-X is awarding Techulon Inc., located in the Virginia Tech Corporate Research Center in Blacksburg, VA, USA, up to $785,000 in non-dilutive funding to develop a new class of antimicrobial that would kill drug-resistant bacteria by targeting […]
CARB-X Funds BioVersys
BioVersys’ new medicine would be used as a stand-alone to treat uncomplicated skin and skin structure infections (SSSI) or in combination with antibiotics for more severe infections.
Antibiotics Are Losing Their Power against Deadly Infections. Can We Fix the Problem?
Kevin Outterson mentioned in NBC News.
Will Viruses Save Us from Superbugs?
BU Law professor Kevin Outterson and CARB-X featured in the Productivity Hub.
Superbug Detector Is First Diagnostic to Launch from CARB-X
BU Law professor Kevin Outterson and CARB-X featured in BU Today.
Procarta Receives CARB-X Award of up to $9.2 Million
Stevenage, UK, 17th September 2019 / Sciad Newswire / Procarta Biosystems, a privately held UK-based biotech company, today announced a CARB-X award of up to $9.2 million to progress its pipeline of antibiotic precision medicines. The award includes initial non-dilutive funding up to $2.2 million with a further $7.0 million available if certain project milestones […]
$1.6 Million Dollars Awarded to Develop Staphylococcus Aureus Bacteria Vaccine
Kevin Outterson and CARB-X are featured in Vax Before Travel.